Longevity medicine is often portrayed as a premium offering: precision protocols and exclusive access to emerging therapeutics for those with the means to seek them out. This captures something true about the field today, but it is an incomplete picture. The field's own science points toward something broader: a wider definition of care, wider reach for patients, and a commitment to widen access as new tools are proven.
The core of contemporary longevity medicine rests on the geroscience hypothesis: that aging itself is the primary shared driver of the diseases that kill and disable us as we grow older — metabolic dysfunction, heart disease, stroke, cancer, and dementia [1]. Target aging directly, the hypothesis goes, and you can slow the onset of aging-related diseases and extend the period of healthy life. The goal is not just more years, but more years worth living, preserving the health and function that allow people to do what matters to them.
The clinical armamentarium is expanding to match this ambition. The foundations of healthy aging, icluding exercise, nutrition, sleep, stress management, social connection, and avoiding known accelerants of aging like cigarette smoking and excess alcohol, remain the most evidence-supported interventions available. Alongside them, emerging tools including mTOR inhibitors, senolytics and senomorphics, mitochondrial bioenergetics interventions, and epigenetic reprogramming are generating serious scientific interest and entering clinical trials. “Precision geromedicine” takes the vision further: profiling molecular data across genomics, proteomics, metabolomics, and epigenomics, together with digital biomarkers and psychosocial and environmental factors, to tailor care to each person's biological profile [2]. Once validated, this framework could transform how aging is managed across a lifetime.
This is the typical presentation of longevity medicine. The question this leaves unanswered is plain: are the field's tools reaching those who need them most?
The Biology of Inequality
Across medicine, the most sophisticated care tends to reach those with more resources, time, and access to medical care. Longevity medicine is no exception. But the biology of aging makes the stakes of this especially clear.
Individuals from lower socioeconomic backgrounds age faster, on average, than those from higher ones. This is not a new observation. The Whitehall studies demonstrated a social gradient in health across employment grades in the British civil service [3]. Subsequent research identified the mechanisms, including chronic stress, financial insecurity, poor nutrition, housing instability, and the physiological burden of discrimination. These mechanisms drive measurable changes in stress hormone regulation, inflammatory signaling, and cellular repair [4]. This is why psychosocial isolation is now recognized as a formal hallmark of biological aging, on par with cellular senescence and mitochondrial dysfunction [2].
Epigenetic clocks offer new ways to measure rates of biological aging. These tools estimate biological age from genome-wide DNA methylation patterns, markers that shift as cells age and predict mortality and aging-related disease risk [5]. It turns out that, because the social determinants of health also track aging, the resulting clock-derived estimates of biological aging reflect income, education, and cumulative stress exposure as well [6, 7]. And the gap between biological and chronological age tends to be widest for those facing the greatest social and economic adversity. Thus, in effect, the science of longevity and the science of health equity are describing many of the same mechanisms.
A Wider Scope
This calls for longevity medicine to widen its scope in three ways.
First, the field should define a longevity intervention more broadly than a drug or biomarker panel. The WHO frames the goal of healthy aging as preserving intrinsic capacity, which consists in the physical and cognitive resources that allow people to function and engage with life as they age. That capacity depends on more than clinical care. It depends on the conditions of daily life — access to safe places to exercise, food environments that make good nutrition realistic, supportive workplaces, and conditions that sustain social connection. These conditions are largely structural, but they operate on the same biological mechanisms that longevity medicine targets. A serious longevity practice treats them as part of the clinical picture.
Second, the field should reach more people. Many of those aging fastest remain least connected to frontier medicine. The science applies to them as much as anyone; access simply has not extended that far. Telehealth is changing that. Specialist longevity care has historically required proximity to major medical centers and the resources to navigate a fragmented system. Platforms that deliver this care remotely, including lab testing, clinical consultations, and longitudinal monitoring, remove much of that barrier. The reach of the field need not be limited by geography.
Third, the field should extend this same commitment as its frontier tools mature. Precision geromedicine remains aspirational in important respects: the mechanisms underlying many aging-related targets are still being elucidated, and clinical protocols for deploying them are not yet standardized. Practices working at this frontier are helping to establish evidence-based longevity care as the science develops. As that science matures and costs fall, the same widening should apply here too. These tools should eventually reach beyond those already well-served by medicine.
Conclusion
Longevity medicine is being built collectively by researchers, clinicians, policy-makers and patients. The shared vision should be a field that extends healthy life not just further, but wider.
By Dr. Nicolai Wohns | Ethics & Longevity Medicine Advisor
Nicolai Wohns, MD, is a physician and PhD candidate in philosophy at the University of Washington, where his research focuses on the ethics of aging and geroscience. He serves as ethics and longevity medicine advisor at Arora Health & Aesthetics.
With over eight years of experience in acute hospital care, he brings a grounded clinical perspective to his scholarship and advisory work, helping shape responsible pathways for translating longevity science into practice. Within Arora’s clinical leadership, Dr. Wohns helps guide the development of longevity medicine that is compassionate, evidence-driven, and ethically grounded, advancing innovation that supports both patients and communities.
References
Kennedy BK, Berger SL, Brunet A, et al. Geroscience: linking aging to chronic disease. Cell. 2014;159(4):709–713.
Kroemer G, Maier AB, Cuervo AM, et al. From geroscience to precision geromedicine: understanding and managing aging. Cell. 2025;188(8):2043–2062.
Marmot MG, Smith GD, Stansfeld S, et al. Health inequalities among British civil servants: the Whitehall II study. Lancet. 1991;337(8754):1387–1393.
World Health Organization Commission on Social Determinants of Health. Closing the Gap in a Generation: Health Equity Through Action on the Social Determinants of Health. Geneva: World Health Organization; 2008.
Lu AT, Quach A, Wilson JG, et al. DNA methylation GrimAge strongly predicts lifespan and healthspan. Aging (Albany NY). 2019;11(2):303–327.
Fiorito G, McCrory C, Robinson O, et al. Socioeconomic position, lifestyle habits and biomarkers of epigenetic aging: a multi-cohort analysis. Aging (Albany NY). 2019;11(7):2045–2070.
Krieger N, Testa C, Chen JT, et al. Epigenetic aging and racialized, economic, and environmental injustice: NIMHD Social Epigenomics Program. JAMA Netw Open. 2024;7(7):e2421832.
